Yu Shyr

A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. Read More

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients also revealed cancer-specific factors associated with increased mortality. Read More

A multidisciplinary team of investigators at Vanderbilt University and Vanderbilt University Medical Center has received a program project grant from the National Cancer Institute to explore extracellular RNA in colorectal cancer. Read More

Data science likely will revolutionize a number of disciplines in the coming years. Yet Vanderbilt experts say we’ve barely reached the beginning stages of unlocking the full potential of data science—or understanding how to use it responsibly. Read More

Clinical trials expert Roger Lewis, MD, PhD, right, poses with Vanderbilt’s Yu Shyr, MD, following his recent Discovery Lecture. Lewis is chair of Emergency Medicine at Harbor-UCLA Medical Center in Los Angeles. Read More

Yu Shyr, Ph.D., Harold L. Moses Professor of Cancer Research and director of the Vanderbilt Center for Quantitative Sciences, has been named chair of Vanderbilt’s Department of Biostatistics. He will assume the post Sept. 1. Read More

A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Read More

Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine. Read More

Two Vanderbilt-Ingram Cancer Center (VICC) leaders have been named to a panel of the Institute of Medicine (IOM) to help shape national policies on the use of biomarkers for targeted cancer therapies. Read More

Vanderbilt University Medical Center has stepped up its support of research aimed at cracking the mysteries of the genome, the master DNA code. Read More

Vanderbilt-Ingram Cancer Center researchers have identified how one of the genes most commonly mutated in lung cancer may promote such tumors. Read More

Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer. Read More

A gene signature may be useful in predicting outcomes for patients with rhabdomysarcoma, a form of cancer most commonly diagnosed in children. Read More